METABOLISM AND ABSORPTION OF l‐3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSON'S DISEASE

Cotzias G. C., 1968, Parkinsonism and dopa, Trans. Assoc. Amer. Phys., 81, 171

Cotzias G. C., 1969, Modification of parkinsonism—chronic treatment with l‐dopa, New Eng. J. Med, 280, 337, 10.1056/NEJM196902132800701

Godwin‐Austen R. B., 1969, Effects of l‐dopa in Parkinson's disease, Lancet, 2, 2

10.1001/archneur.1969.00480160015001

10.7326/0003-4819-72-1-29

10.1111/j.1476-5381.1969.tb09522.x

10.1136/bmj.1.5693.400

Barbeau A., 1969, l‐dopa therapy in Parkinson's disease: a critical review of nine years' experience, Canad. Med. Ass. J., 101, 91

Klawans H. L., 1969, Treatment of parkinsonism with l‐dopa, Dis. Nerv. System., 30, 737

10.1016/0006-3002(59)90652-3

10.1111/j.1471-4159.1959.tb13216.x

Sharman D. F., 1963, Homovanillic acid in the candate nucleus, J. Physiol. (London), 169, 95

Vogt M., 1965, Effect of drugs on metabolism of catecholamines in the brain, Brit. Med. Bull., 21, 57, 10.1093/oxfordjournals.bmb.a070357

10.1016/0024-3205(64)90161-4

10.1038/1801200a0

10.1126/science.129.3352.844

Hornykiewicz O., 1963, Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3‐Hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen, Wien. Klin. Wschr., 75, 309

Hornykiewicz O., 1964, Dopamine (3‐hydroxytryramine) and brain function, Pharmacol. Rev., 18, 925

Patel A. R., 1966, l‐2,3 dihydroxyphenylalamine, Fortschr. Arzneimittelforsch., 9, 223

10.1016/B978-0-08-011698-3.50012-7

Udenfriend S., 1966, Tyrosine hydroxylase, Pharmacol. Rev., 18, 43

Blaschko H., 1939, The specification of l‐dopa decarboxylase, J. Physiol. (London), 13, 96

10.1016/0006-2944(70)90032-3

Sourkes T. L., 1966, Dopa decarboxylase: substrates, coenzymes and inhibitors, Pharmacol. Rev., 18, 53

Vogel W. H., 1969, Nonenzymatic decarboxylation of dihydroxyphenylalanine, Naturvissenschaften., 56, 56

10.1016/S0079-6468(08)70199-1

10.1001/archneur.1969.00480080087010

10.1212/WNL.13.1.73

10.1016/0006-8993(67)90154-0

Morgan J. P., 1970, Metabolism of oral l‐dopa in Parkinsonian patients, Clin. Res., 18, 342

Peaston M. J. T.&J. R.Bianchine.1970.Metabolic fate of l‐dopa before and during treatment of Parkinson's disease.Clin. Pharmacol. Ther.In press.

Hare T. A., 1970, Plasma and urinary levels of dopa and other amino acids in l‐dopa treated patients with Parkinson's disease, Fed. Proc., 29, 952

10.1007/BF01895283

10.1172/JCI106196

10.1038/213802a0

10.1007/BF00407039

Bartholini C., 1968, Cerebral accumulation and metabolism of C14‐l‐dopa after selective inhibition of peripheral decarboxylase, J. Pharmacol. Exp. Ther., 161, 14

Rivera‐Calimlim L., 1970, l‐dopa metabolism by rat gut in vitro, Clin. Res., 18, 343

Malawer S. J., 1967, An improved turbidimetric analysis of polyethylene glycol utilizing an emulsifier, Gastroenterology., 53, 53, 10.1016/S0016-5085(19)34232-5

Schanker L., 1962, Passage of drugs across body membranes, Pharmacol. Rev., 14, 501

10.1016/0006-2952(66)90259-0

Spencer R. P., 1969, Intestinal absorption of amino acid—current concepts, Amer. J. Clin. Nutr., 22, 292, 10.1093/ajcn/22.3.292

10.1136/gut.6.5.411

Calimlim L. R., 1970, l‐dopa treatment failure: explanation and correction, Brit. Med. J.

10.1111/j.2042-7158.1969.tb08258.x

Siegfried J., 1969, Treatment of parkinsonism with l‐dopa in association with a decarboxylase inhibitor, Pharm Clinica., 2, 2